The UK and US have concluded a landmark commercial pact that will preserve zero duties on British drug shipments going into the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has pledged to raise spending on medicines through the NHS. This pledge ensures that duties on these key exports will remain at nothing for a timeframe of three years.
This development comes after previous warnings to significantly raise import taxes on patented drug products, with figures discussed as high as one hundred percent.
"This arrangement with the Britain strengthens the international landscape for cutting-edge drugs and establishes much-needed fairness to American-British drug exports," an announcement said.
Commercial Impact
Drugs constitute one of the UK's biggest export categories to the US, which is by far the largest market for large UK drugmakers.
Trade data show that in the one-year period to the end of September, the UK shipped drugs worth £11.1bn to the US. This amount accounted for 17.4% of all goods exports in that timeframe.
"This guarantee safeguards employment, boosts funding and sets the stage for the UK to emerge as a global hub for life sciences," the Business and Trade Secretary commented.
Key NHS Changes
The deal includes several key pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it judges new treatments to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a aim to raise total NHS spending on treatments from 0.3% of GDP to 0.6 percent over the next decade.
- Payback Limit: The amount drug companies must return to the NHS to stay within budget will be limited at 15%. Last year, repayments were more than 20%.
Broader Context
The pact comes amid a ongoing row between the pharmaceutical industry and the UK government over medicine costs and NHS adoption.
These tensions were heightened by claims that American patients were charged a premium for the equivalent treatments than people in the UK and Europe.
Recently, several large manufacturing plans in the UK have been delayed or scrapped, while substantial investments have been directed toward American operations.
A senior figure publicly accepted that the NHS must spend more on drugs, noting that its spending on drugs had shrunk as a percentage of its total funding over the past decade.
